Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
This multicenter study identifies peripheral blood stem cell use as a key risk factor for early inflammatory complications post-haploidentical HSCT in children, linking these events to refractory acute and chronic graft-versus-host disease.
This study identifies distinct tumor immune microenvironment subgroups in diffuse large B-cell lymphoma based on CD163 and CD11c expression, revealing prognostic significance and potential therapeutic stratification with checkpoint inhibito
Excess folic acid promotes erythropoiesis impairment in myelodysplastic neoplasms via the FOLR2-IRF2BP2 axis, revealing potential therapeutic targets involving dietary folic acid restriction and pathway inhibition.
The AZALEA-TIMI 71 study demonstrates that factor XI inhibition with abelacimab reduces bleeding risk in atrial fibrillation patients regardless of prior oral anticoagulation experience, with a potentially greater absolute benefit in antico
This study evaluates survival and relapse outcomes of total body irradiation versus chemotherapy conditioning regimens in haploidentical hematopoietic cell transplantation for adult AML patients in first remission, revealing no clear surviv
The UK NCRI phase II trial demonstrates pembrolizumab with localized radiotherapy yields meaningful response rates and durable control in relapsed/refractory advanced cutaneous T-cell lymphoma, marking an important step in improving outcome
Dysfunction in SLF2 and SMC5 causes premature hematopoietic stem cell aging, bone marrow failure, and early-onset myelodysplastic syndrome in Atelis Syndrome, defining a novel inherited bone marrow failure disorder.
RAAS inhibitors, used for kidney protection in sickle cell disease, may significantly exacerbate anemia by impairing erythropoiesis, warranting close hemoglobin monitoring in this vulnerable population.
This study evaluates non-invasive biomarkers to differentiate essential thrombocythemia, premyelofibrosis, and overt myelofibrosis, revealing distinct inflammatory and immune profiles and supporting a disease continuum model.
Biallelic loss-of-function mutations in BPNT1 are identified as a new genetic cause of vitamin B12-dependent megaloblastic anemia, linked to disrupted ribosome biogenesis and impaired ileal vitamin B12 absorption in mouse models.
This study evaluates the incidence, severity, and predictors of extracranial bleeding in atrial fibrillation patients on oral anticoagulants, highlighting its substantial burden beyond major bleeds and informing bleeding risk management.
This multicenter study evaluates autologous stem cell transplantation (ASCT) in POEMS syndrome, showing significant hematologic response, durable survival, and manageable toxicity, highlighting ASCT’s pivotal role in treatment.
Anti-PD-1 therapy has transformed classical Hodgkin lymphoma management, demonstrating safety, feasibility, and durable efficacy across treatment settings—from relapsed/refractory disease to frontline therapy.
BIA-ALCL is a heterogeneous T cell lymphoma marked by immunosuppressive tumor microenvironments that promote tumor survival and proliferation, revealing potential targets for advanced disease therapy.
Low-level FLT3-ITD microclones, detected via NGS in young adults with AML, independently increase relapse risk comparable to macroclones, challenging current risk stratification and underscoring the need to integrate advanced genetic testin
This retrospective EBMT study identifies secondary autoimmune and inflammatory diseases as rare but significant complications following allo-HSCT, highlighting their incidence, risk factors, and impact on patient survival, calling for impro
This study reveals that certain high-risk cytogenetic abnormalities continue to influence progression-free survival in multiple myeloma patients even after achieving deep MRD negativity post-ASCT, highlighting the need for tailored post-tra
A prospective study finds that baseline EASIX and day 14 sC5b-9 are independently associated with TA-TMA after allo-HCT, with combined stratification identifying high-risk adults.
Five-year results from the OPTIC trial show that starting ponatinib at 45 mg then reducing to 15 mg upon response provides the best long-term efficacy and manageable safety in resistant CP-CML, particularly for T315I patients.
A study of 2,577 haploidentical transplants shows that extended HLA haplotypes, including a class III SNP, significantly influence mortality and relapse, potentially improving donor selection.
Open language-specific specialty feeds and department pages.